Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Table 1 Study visit schedule: BENEFIT-Korea study

Variable	Visit 1 (baseline)	Visit 2 (follow-up)	Visit 3 (follow-up/last visit)
Schedule (wk)	0	12 ± 2^a	24 ± 2 ^a
Informed consent form	√
Inclusion/exclusion criteria	√
Patient demographics	√
Height/weight/waist size^b	√	√	√
History of previous anti-hypertensive drugs	√
Medical history^c	√
Administrative status of nebivolol	√	√	√
Concomitant medications	√	√	√
Laboratory test^d	√	√	√
Blood pressure measure^e	√	√	√
Safety assessment		√	√

^aPatients were allowed ±2 weeks period from the designated schedules for follow-up visits. ^bHeight was measured only at baseline (height, weight, and waist size) was recorded up to one decimal. ^cPast medical history and present medical history within 6 months from baseline were recorded. In case a medical history was collected after baseline, it was recorded in the safety analysis set. ^dGlucose (HbA1c, fasting blood sugar), total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and other laboratory tests, when done, were recorded. Of the laboratory test results collected, the values pointing to adverse events were recorded in the safety analysis set. ^eBlood pressure was measured when subjects were stable - mean seated trough cuff blood pressure was measured

ISSN: 2056-5909